Skip to main content
. 2013 Apr 2;121(21):4287–4294. doi: 10.1182/blood-2012-12-471680

Table 1.

Characteristics of older patients initiating induction chemotherapy for AML (N = 74)

Characteristics Median (25th, 75th) or %
Demographics
 Age (y) 68.8 (65.8,74.3)
 60-69 y 55.4
 70-79 y 33.8
 ≥80 y 10.8
 Gender (male) 54.1
 Race (white) 96.0
Education level*
 <High school 25.0
 High school 23.6
 College/above 51.4
Clinical
 Hemoglobin (g/dL) 9.4 (8.5, 10.2)
 LDH (U/L) 225.5 (180.0, 357.0)
 White cell count (×103/mm3) 3.3 (1.7, 16.9)
 Creatinine (mg/dL) 1.0 (0.8, 1.2)
 Body mass index 27.9 (24.9, 31.9)
 ECOG score (≤1) 78.1
 Prior MDS 28.4
 Cytogenetic risk group
 Favorable 4.1
 Intermediate 64.4
 Poor 31.5
 Coronary artery disease 17.6
 Chronic obstructive pulmonary disease 13.5
 Diabetes mellitus 21.6
 Congestive heart failure 4.1
Treatment§
 Anthracycline+cytarabine 54.1
 Anthracycline+cytarabine+bortezomib 17.6
 Anthracycline+cytarabine+etoposide 16.2
 Cytarabine+amonafide 9.5
 Other 2.6

LDH, lactate dehydrogenase.

*

Education level was unavailable for one subject.

ECOG score was unavailable for two subjects.

Cytogenetic test results were unavailable for one subject.

§

Anthracycline dosing: daunorubicin 60 mg/m2 (61%), 45 mg/m2 (13%); idarubicin 12 mg/m2 (24%), 20 mg/m2 (2%); cytarabine dosing 100 mg/m2 (77%), 200 mg/m2 (23%).